Changes in mitochondrial structure and function are known to occur in age-associated disorders such as Parkinsons disease, sarcopenia and metabolic diseases, including heart-disease and diabetes mellitus (Desler et al., 2012
Isoleucine is an essential amino acid that assists in the utilization of ketone bodies and fatty acids
The role of iron in promoting -syn aggregation by enhancing -syn mRNA expression Iron promotes -syn aggregation by increasing its mRNA translation
Priority Applications (1) Applications Claiming Priority (4) Publications (2) Family ID=8209663 Family Applications (2) Family Applications Before (1) Country Status (23) Families Citing this family (21) Family Cites Families (4) 1992 1992-05-30 EP EP92109145A patent/EP0572688B1/en not_active Expired - Lifetime 1992-05-30 ES ES92109145T patent/ES2103854T3/en not_active Expired - Lifetime 1992-05-30 DE DE69219590T patent/DE69219590T2/en not_active Expired - Lifetime 1992-05-30 AT AT92109145T patent/ATE152734T1/en active 1992-05-30 DK DK92109145.0T patent/DK0572688T3/en active 1993 1993-05-28 WO PCT/EP1993/001352 patent/WO1993024521A1/en not_active Ceased 1993-05-28 AU AU43196/93A patent/AU4319693A/en not_active Abandoned 1993-05-28 PL PL93302304A patent/PL176208B1/en not_active IP Right Cessation 1993-05-28 JP JP6500207A patent/JP2783681B2/en not_active Expired - Lifetime 1993-05-28 US US08/185,883 patent/US6211151B1/en not_active Expired - Fee Related 1993-05-28 ES ES93912825T patent/ES2107033T3/en not_active Expired - Lifetime 1993-05-28 CA CA002114313A patent/CA2114313C/en not_active Expired - Lifetime 1993-05-28 DK DK93912825.2T patent/DK0601154T3/en active 1993-05-28 HU HU9400252A patent/HU224073B1/en not_active IP Right Cessation 1993-05-28 CZ CZ94205A patent/CZ284972B6/en not_active IP Right Cessation 1993-05-28 EP EP93912825A patent/EP0601154B1/en not_active Expired - Lifetime 1993-05-28 UA UA93003868A patent/UA32523C2/en unknown 1993-05-28 SK SK96-94A patent/SK278507B6/en not_active IP Right Cessation 1993-05-28 HK HK97102674A patent/HK1001004A1/en not_active IP Right Cessation 1993-05-28 DE DE69312232T patent/DE69312232T2/en not_active Expired - Lifetime 1993-05-28 RU RU94041224A patent/RU2111214C1/en not_active IP Right Cessation 1993-05-28 RO RO94-00101A patent/RO112506B1/en unknown 1993-05-28 AT AT93912825T patent/ATE155485T1/en active 1994 1994-01-26 FI FI940375A patent/FI120454B/en not_active IP Right Cessation 1994-01-27 KR KR1019940700258A patent/KR0180256B1/en not_active Expired - Fee Related 1994-01-28 BG BG98426A patent/BG61477B1/en unknown 1994-01-28 NO NO940299A patent/NO310027B1/en not_active IP Right Cessation 1997 1997-08-07 GR GR970402020T patent/GR3024379T3/en unknown 1997-10-01 GR GR970402552T patent/GR3024905T3/en unknown 1998 1998-12-02 US US09/203,921 patent/US6268346B1/en not_active Expired - Fee Related
Oral DMTs: An alternative to injectable therapies In 2010, fingolimod (Gilenya , Novartis, Switzerland) was the first oral MS DMT approved by the FDA, with teriflunomide (Aubagio , Genzyme, France) following in 2012 and cladribine (Mavenclad , Merck, Germany) in 2017 approved by the EMA
